Navigation Links
BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
Date:2/29/2012

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- BrainCells Inc., a leading biotechnology company developing novel compounds for the treatment of central nervous system (CNS) diseases, announced today that the Phase 1 single ascending dose (SAD) study of BCI-838 has been successfully completed and that the company has initiated the Phase 1 multiple ascending dose (MAD) study. The SAD study evaluated BCI-838 for safety, tolerability, pharmacokinetics and food effect in healthy male subjects.  Single oral doses of BCI-838 up to 900 mg were administered and the drug was well tolerated.  No serious adverse events were reported and all adverse events were mild in intensity, transient, and resolved without sequelae.

"BCI-838's biological activity mimics that of ketamine, an intravenous anesthetic, which has been shown to be efficacious in treating patients with TRD.   Since ketamine is associated with a number of unwanted side effects such as short-term dissociation and psychosis, safer compounds that act in a similar fashion promise to revolutionize the way the disease is managed for these patients," said Robert Williamson, Chief Executive Officer.

BCI-632 increases synaptic glutamate by inhibiting the mGlu2/3 auto-receptor, which is located predominantly at the pre-synaptic site.  As in the case of ketamine, the long-lasting efficacy of BCI-632 can be blocked by either inhibition of AMPA receptors, mTOR or the BDNF signaling pathway. In contrast to ketamine, BCI-632 does not cause psychosis or dissociative effects. In addition, BCI-632 also stimulates serotonin release and, after chronic dosing, hippocampal neurogenesis. 

"BCI-838 is an oral prodrug for the active compound BCI-632 that is an mGluR2/3 antagonist," said John Hutchinson, Ph.D. Senior Vice President of Research.  "BCI-632 has been shown to work acutely in a range of animal models of depression, anxiety, cognition and Alzheimer's disease."

"B
'/>"/>

SOURCE BrainCells Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman
2. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
3. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
4. eCardio Announces Publication of Manuscript on The Use of Mobile Cardiac Telemetry to Improve Diagnostic Accuracy and Enable More Efficient Patient Care
5. PTCB Announces New Employer Partnership Program
6. CardioInsight Announces Addition of Jim Hassett to Senior Management Team
7. JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy
8. Mindray Announces 2011 Fourth Quarter and Full Year Results
9. Cempra, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
10. Tibet Pharmaceuticals, Inc. Announces Intent to Go Private
11. Delcath Announces First CHEMOSAT Procedures in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals ... 2a study of lonafarnib in patients with chronic ... conducted at the National Institutes of Health (NIH) ... .  The double-blinded, randomized, placebo-controlled, dose ascending study ... daily and 200 mg twice daily for 28 ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... , a leading provider of therapeutic drug monitoring and ... today the appointment of David Cohen to Chief Operating ... responsible for new business analysis and development to expand ... Millennium,s legislative initiatives and community outreach programs. ...
... Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast:What: ... presented at ESCWhen: , Wednesday, September 1, 2010 at 4:00 ... Live on the Internet.  Simply log onto our Web site listed ... a replay of the webcast will be available for a limited ...
Cached Medicine Technology:Millennium Laboratories Announces New Chief Operating Officer David Cohen 2
(Date:12/24/2014)... As 2014 draws to a close, ... investing time and money into a new or tankless ... specializes in tankless and eco-friendly products or service. Greenstar ... heater in 2015 to research “green” and environmentally friendly ... Home Services specializes in eco-friendly and environmentally conscious ...
(Date:12/24/2014)... York (PRWEB) December 24, 2014 In ... the United States rode bicycles, hand cycles and recumbent ... D.C. in the inaugural CanAm Veterans’ Challenge . ... non-profit World T.E.A.M. Sports about this inspiring ride, is ... more than 50 full color photographs taken during the ...
(Date:12/24/2014)... 23, 2014 (HealthDay News) -- Each year, more than ... the United States occur because of extreme heat conditions, ... study finds that heat stroke is the leading cause ... as kidney failure and urinary tract infections, also put ... soar. The new data should help health care ...
(Date:12/24/2014)... -- Though most patients with obsessive-compulsive disorder (OCD) can ... percent to 20 percent have a form of the ... However, patients with this so-called "refractory OCD" do ... brain surgery that disables certain brain networks believed to ... patients most likely to benefit from the surgery, known ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
Breaking Medicine News(10 mins):Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 3Health News:Heat Stroke, Kidney Failure Help Drive Illnesses From Extreme Heat 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... Executive ... Chairman, SOUTH SAN ... company focused on the discovery,and development of drugs for major medical needs ... will step down today as President and Chief Executive Officer to,pursue another ...
... SAN DIEGO, Oct. 1 Amylin Pharmaceuticals,Inc. ... the U.S. Food and Drug,Administration (FDA) has ... pen-injector devices for administering SYMLIN(R),(pramlintide acetate) injection. ... dosing to improve mealtime glucose control. ...
... Presented at ERS 17th Annual Congress -, ... Inc.,today announced the submission of a pre-market approval ... (FDA) requesting regulatory,approval to market the Emphasys endobronchial ... Zephyr EBV is a minimally invasive and potentially,reversible ...
... have been homeless for any period of time after ... problems accessing health care than those with stable housing ... of Archives of Pediatrics & Adolescent Medicine, one of ... any period of time after leaving the foster care ...
... 1 Highlands Behavioral,Health System, a UHS facility, ... of Excellence for teens in crisis. The new ... Highlands Behavioral,Health ( http://www.highlandsbhs.com ) in Littleton, Colo. ... said the,Adolescent Center of Excellence represents an expansion ...
... was recently announced,as a silver winner in ... by,ComPsych Corporation. Concentra was selected based on ... achieved results. Concentra, a leader in ... commitment to better health and wellness among ...
Cached Medicine News:Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3Health News:New Denver Area Program Developed For Teens in Crisis 2Health News:Concentra Honored With Silver Health at Work(SM) Award by ComPsych(R) Corp. 2
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... Pachymeter [i.e., PalmScan P2000] device is ... which incorporates A-mode pulsed-echo ultrasound,technology, and ... measure the corneal thickness (CT) and,epithelium ... P2000 includes two software user,interfaces; a ...
Medicine Products: